Table 2. Baseline Clinical and Procedural Characteristics by Sex and Randomized Treatment Assignment.
| Parameters | Women (n = 1698) | Men (n = 5421) | ||||
|---|---|---|---|---|---|---|
| No. (%) | P value | No. (%) | P value | |||
| Ticagrelor + placebo (n = 846) | Ticagrelor + aspirin (n = 852) | Ticagrelor + placebo (n = 2709) | Ticagrelor + aspirin (n = 2712) | |||
| Age, mean (SD), y | 65.4 (9.6) | 65.7 (9.5) | .61 | 63.4 (10.2) | 63.3 (10.4) | .61 |
| Non-White racea | 289 (34.2) | 283 (33.2) | .68 | 821 (30.3) | 803 (29.6) | .58 |
| BMI, mean (SD) | 28.8 (6.4) | 28.8 (6.4) | .93 | 28.5 (5.2) | 28.5 (5.3) | .82 |
| Enrolling region | ||||||
| North America | 339 (40.1) | 386 (45.3) | .08 | 1145 (42.3) | 1102 (40.6) | .44 |
| Europe | 289 (34.2) | 256 (30.0) | 962 (35.5) | 1002 (36.9) | ||
| Asia | 218 (25.8) | 210 (24.6) | 602 (22.2) | 608 (22.4) | ||
| Diabetes | 308 (36.4) | 310 (36.4) | .99 | 1011 (37.3) | 991 (36.5) | .55 |
| Treated with insulin | 83 (26.9) | 124 (40.0) | <.001 | 252 (24.9) | 250 (25.2) | .88 |
| Chronic kidney disease | 154 (18.9) | 193 (23.5) | .02 | 400 (15.4) | 364 (14.0) | .14 |
| Anemia | 190 (23.5) | 189 (22.9) | .79 | 485 (18.7) | 465 (17.9) | .46 |
| Current smoker | 136 (16.1) | 152 (17.9) | .32 | 590 (21.8) | 670 (24.7) | .01 |
| Hypercholesterolemia | 477 (56.4) | 523 (61.4) | .04 | 1680 (62.0) | 1623 (59.8) | .10 |
| Hypertension | 641 (75.8) | 658 (77.2) | .48 | 1939 (71.6) | 1916 (70.7) | .46 |
| Peripheral arterial disease | 50 (5.9) | 62 (7.3) | .26 | 195 (7.2) | 182 (6.7) | .48 |
| Previous MI | 181 (21.4) | 174 (20.4) | .62 | 839 (31.0) | 846 (31.2) | .86 |
| Previous PCI | 258 (30.5) | 294 (34.5) | .08 | 1244 (45.9) | 1202 (44.3) | .24 |
| Previous CABG | 53 (6.3) | 55 (6.5) | .88 | 309 (11.4) | 293 (10.8) | .48 |
| Previous major bleed | 8 (0.9) | 11 (1.3) | .50 | 23 (0.8) | 21 (0.8) | .76 |
| Indication for PCI | ||||||
| ACS | 580 (68.6) | 580 (68.2) | .86 | 1693 (62.5) | 1761 (64.9) | .06 |
| Stable CAD | 266 (31.4) | 271 (31.8) | 1015 (37.5) | 951 (35.1) | ||
| Radial artery access | 618 (73.0) | 578 (67.8) | .02 | 1982 (73.2) | 2008 (74.0) | .46 |
| Multivessel CAD | 458 (54.1) | 483 (56.7) | .29 | 1814 (67.0) | 1711 (63.1) | .003 |
| Target vessel | ||||||
| Left main | 35 (4.1) | 40 (4.7) | .58 | 131 (4.8) | 147 (5.4) | .33 |
| LAD | 514 (60.8) | 517 (60.7) | .98 | 1479 (54.6) | 1493 (55.1) | .74 |
| LCX | 204 (24.1) | 241 (28.3) | .051 | 947 (35.0) | 905 (33.4) | .22 |
| RCA | 294 (34.8) | 299 (35.1) | .88 | 949 (35.0) | 958 (35.3) | .82 |
| Vessels treated, mean (SD), No. | 1.24 (0.48) | 1.29 (0.52) | .046 | 1.29 (0.52) | 1.29 (0.53) | .90 |
| Lesions treated, mean (SD), No. | 1.44 (0.69) | 1.50 (0.73) | .07 | 1.56 (0.76) | 1.53 (0.76) | .18 |
| Lesion morphologyb | ||||||
| Moderate/severe calcification | 139 (16.4) | 111 (13.0) | .048 | 359 (13.3) | 378 (13.9) | .46 |
| Bifurcation | 105 (12.4) | 95 (11.2) | .42 | 329 (12.1) | 337 (12.4) | .75 |
| Total occlusion | 42 (5.0) | 50 (5.9) | .41 | 180 (6.6) | 174 (6.4) | .73 |
| Thrombotic | 97 (11.5) | 81 (9.5) | .19 | 272 (10.0) | 299 (11.0) | .24 |
| Total stent length, mean (SD), mmc | 38.1 (22.1) | 37.1 (22.0) | .39 | 40.7 (24.8) | 40.4 (24.9) | .65 |
| Minimum stent diameter, mean (SD), mm | 2.8 (0.5) | 2.8 (0.5) | .79 | 2.9 (0.5) | 2.9 (0.5) | .21 |
Abbreviations: ACS, acute coronary syndrome; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CABG, coronary artery bypass graft; CAD, coronary artery disease; LAD, left anterior descending; LCX, left circumflex; MI, myocardial infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery.
a
Includes Black, Asian, and other races.
b
Lesion morphology assessed by operators.
c
Stent length calculated by operators.